Phase I
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
Oncoceutics announced today that the first patient has been treated in a clinical trial of ONC201 for pediatric patients with brain tumors that contain a specific mutation called the histone H3 K27M mutation.
During its financial report this morning, Pfizer released an update of its pipeline which includes the discontinued projects.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
The surprising disclosure was outlined in a November 2017 letter from the FDA.
After a brief stumble with UCART123 that resulted in a clinical hold last year, Cellectis is moving on with its study.
MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial.
The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.
PRESS RELEASES